Reuters logo
10 months ago
BRIEF-4SC: subgroup analysis of phase II study with resminostat
October 5, 2016 / 8:46 AM / 10 months ago

BRIEF-4SC: subgroup analysis of phase II study with resminostat

Oct 5 (Reuters) - 4SC AG :

* Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat

* 4SC AG and Yakult Honsha retrospectively analyzed data of randomized, multicenter phase II study, conducted by Yakult Honsha in Japan and South Korea Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below